IDEXX Laboratories, Inc. — Form 10-Q Summary
Business context and reporting period
Unaudited quarterly report for the three and six months ended June 30, 2013, filed July 23, 2013. IDEXX provides veterinary diagnostics and information-management products and services through its Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other segments. The company retrospectively revised 2012 segment presentation following the combination of its Livestock and Dairy businesses into LPD.
Key financial metrics
| Metric | Q2 2013 | Q2 2012 | Change |
|---|---|---|---|
| Revenue | $352.6 million | $335.6 million | 5.0% |
| Gross profit | $197.7 million | $184.7 million | 7.0% |
| Gross margin | 56.1% | 55.0% | +110 bps |
| Operating income | $78.8 million | $75.8 million | 3.9% |
| Operating margin | 22.3% | 22.6% | -30 bps |
| Net income attributable to IDEXX | $54.0 million | $51.3 million | 5.2% |
| Diluted EPS | $0.99 | $0.91 | 8.8% |
| Metric | Six months ended June 30 | Change | |
|---|---|---|---|
| 2013 | 2012 | ||
| Revenue | $684.7 million | $658.3 million | 4.0% |
| Gross profit | $381.7 million | $359.5 million | 6.2% |
| Gross margin | 55.7% | 54.6% | +110 bps |
| Operating income | $139.9 million | $136.2 million | 2.7% |
| Operating margin | 20.4% | 20.7% | -30 bps |
| Net income attributable to IDEXX | $98.9 million | $92.1 million | 7.4% |
| Diluted EPS | $1.80 | $1.63 | 10.4% |
Q2 organic revenue growth was 5.5%; six-month organic growth was 4.4%. CAG was the primary growth driver, with Q2 revenue up 6.3% and six-month revenue up 4.8%. Q2 CAG growth was led by VetLab consumables and reference laboratory services. VetLab instrument revenue declined, partly because a reagent-rental program shifts recognition over the rental term.
Q2 CAG gross margin improved to 54.7% from 53.1%, primarily from reference-laboratory efficiencies and pricing. LPD performance weakened materially: Q2 operating income declined 43.3% and gross margin fell to 53.9% from 60.3%, reflecting lower sales, manufacturing costs, currency effects and lower pricing on certain bovine tests.
For the first six months, operating cash flow was $100.0 million versus $78.8 million in 2012. Investing cash use was $40.9 million, including $43.7 million of capital expenditures. Financing cash use was $29.1 million, including $206.3 million of share repurchases and $155.5 million of net revolving-facility borrowings. Cash increased to $251.0 million from $224.0 million at December 31, 2012.
Material changes versus the prior comparable period
- Revenue growth was supported by higher reference-laboratory testing, VetLab consumables volumes and pricing; foreign exchange reduced Q2 revenue by approximately $2.7 million and six-month revenue by approximately $4.6 million.
- Gross margin expanded, but operating margin declined slightly as operating expenses grew faster than revenue, particularly personnel, information technology, consulting and research and development costs.
- The company recorded a $4.1 million loss in the first six months related to the bankruptcy of a freight-payment and audit-service provider following employee fraud and control failures at that provider. Potential recovery was uncertain.
- The effective tax rate declined to 30.8% in Q2 and 28.8% for the first six months, versus 31.9% and 31.8%, respectively, primarily because legislation reinstated and retroactively extended the U.S. research and development tax credit.
- In May 2013, IDEXX refinanced its $300 million revolving facility with a five-year, $450 million unsecured facility maturing May 8, 2018. Borrowings were $367.5 million at June 30, 2013, and remaining borrowing availability was $81.5 million.
- The company repurchased 2.3 million shares for $206.3 million during the first six months, compared with 0.7 million shares for $55.0 million in the prior-year period.
- The FTC investigation was finally resolved in February 2013 through a ten-year consent agreement limiting IDEXX to exclusive distribution agreements with two of three specified major distributors.
Guidance, outlook, commentary and risks
The filing does not provide clear numerical full-year revenue or earnings guidance. Management stated that it was cautiously optimistic about gradual macroeconomic improvement but noted that U.S. patient-visit improvement had slowed in the first half of 2013 and that European economic conditions remained challenging. Planned 2013 capital expenditures were approximately $90 million, including headquarters expansion, information technology, manufacturing equipment and reference-laboratory investments.
Management believed cash on hand, operating cash flow and available borrowings would fund operations, capital requirements and strategic growth for at least the next twelve months. Approximately $249.3 million of cash was held by foreign subsidiaries and was subject to material repatriation tax effects.
- Customer demand remains sensitive to economic conditions, veterinary patient visits, pet-owner spending and customers’ capital-purchase decisions.
- Distributor purchasing patterns and concentration can cause reported revenue to differ from underlying end-user demand. The modified MWI agreement permits competing products and may reduce IDEXX’s distribution advantage.
- Foreign currency exposure affected revenue and margins; approximately 42% of Q2 revenue and 41% of first-half revenue came from customers outside the United States.
- The company relies on sole or single-source suppliers and complex biologic manufacturing processes, creating supply, quality and product-recall risks.
- Regulatory changes, including reduced or eliminated European Union BSE testing requirements, pressured LPD revenue and could continue to reduce testing demand.
- The credit facility includes customary covenants and a consolidated leverage-ratio limit of 3-to-1. IDEXX was in compliance at June 30, 2013, but the facility includes provisions that could accelerate obligations following defaults or specified adverse events.
- Cash-flow hedges, foreign exchange movements, changing testing patterns, competition, intellectual-property claims and operational disruptions remain material risks.
Important facts for investors to verify
- Reconcile reported revenue growth with organic growth, currency effects, acquisitions and distributor inventory movements.
- Assess the sustainability of CAG consumables and reference-laboratory growth against declining instrument placements and the reagent-rental accounting model.
- Monitor LPD revenue, gross margin and operating income following European BSE-testing changes and recent manufacturing and currency pressures.
- Review debt availability, leverage compliance, refinancing terms and the liquidity effect of substantial share repurchases.
- Evaluate the recoverability of the $4.1 million freight-service loss and any developments in the provider’s bankruptcy proceeding.
- Consider the tax-rate benefit from the R&D credit separately from underlying operating performance.
- Review the continuing effects of the FTC consent agreement and the non-exclusive MWI arrangement on pricing, distribution and competition.